Clinicopathological features of metaplastic breast carcinoma

Oğuz Ahmet Hasdemir1,A–F, Serhat Tokgöz1,B–D,F, Fulya Köybaşıoğlu1,B,C,E, Harun Karabacak1,C,D, Cüneyt Yücesoy1,B,F, Gökşen İnanç İmamoğlu1,B,F

1 Department of General Surgery, Ministry of Health Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
2 Department of Pathology, Ministry of Health Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
3 Department of Radiology, Ministry of Health Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
4 Department of Medical Oncology, Ministry of Health Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation; D – writing the article; E – critical revision of the article; F – final approval of the article

Address for correspondence
Oğuz Hasdemir
E-mail: oguzhasdemir@gmail.com

Funding sources
None declared

Conflict of interest
None declared

Received on October 9, 2016
Reviewed on November 1, 2016
Accepted on January 5, 2017

Abstract

Background. Metaplastic carcinoma of the breast (MpBC) is defined as a group of heterogeneous malignant neoplasms that contain glandular and non-glandular components with mixed epithelial and mesenchymal differentiations.

Objectives. The aim of this study was to research the clinical and pathological characteristics of MpBC determining its rank among all breast cancers.

Material and methods. Metaplastic carcinoma of the breast was found in 7 out of 1,164 patients who had been diagnosed with breast cancer within the period of 12 years in our hospital. Demographic and clinical characteristics of the patients were retrieved from the patient files, and their final status was verified by a phone call. Diagnoses of the patients were confirmed by examining hematohylen and eosin (H&E) preparations. They were stained immunohistochemically for estrogen receptor (ER), progesterone receptor (PR), C-erbB-2, CK5/6, and EGFR (epidermal growth factor receptor), and the subgroups were determined according to the WHO classification.

Results. All patients were female with a median age of 61 years (41–87 years). Three of them were diagnosed with stage IIB, 2 with IIIB and 1 with IV. Four patients had squamous type of metaplastic cell differentiation, 1 spindle, 1 adenosquamous, and 1 osteosarcomatous. In 6 out of 7 patients, ER, PR and C-erbB-2 expressions were negative immunohistochemically. In the case of squamous metaplasia, estrogen receptor was 10% and progesterone receptor was 5% positive. CK5/6 was positive in 5 cases. Epidermal growth factor receptor was positive in all cases.

Conclusions. Metaplastic carcinoma of the breast is relatively rare and, in our series, its incidence was 0.6%. According to its immunohistochemical characteristics, MpBC can be interpreted as a subgroup of triple-negative breast cancers (TNBC). Five of the presented patients resembled the subgroup of TNBC with a basaloid phenotype. The chemotherapy regimens suggested in the treatment of MpBC are platin in the epithelial subgroup and high-dose anthracycline in the mesenchymal subgroup. There is a need of new studies that evaluate different choices of treatment as MpBC has a bad prognosis and an aggressive nature.

Key words: metaplastic breast cancer, breast cancer, triple-negative breast cancer
Introduction

Breast cancer is the most frequent cancer in women. Metaplastic carcinoma of the breast (MpBC) is a very rare and aggressive subgroup with a bad prognosis within the breast cancers.\textsuperscript{1–3} Metaplastic carcinoma of the breast is defined as a group of heterogeneous malignant neoplasms that contain glandular and non-glandular components with mixed epithelial and mesenchymal differentiations.\textsuperscript{4} Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2/neu, c-erbB-2) are negative in more than 90% of MpBC, while cytokeratin 5/6 (CK5/6), cytokeratin 14, and epidermal growth factor receptor (EGFR) show expressions immunohistochemically.\textsuperscript{5} This subgroup, for which standard treatment protocols have different responses due to its heterogeneous nature, needs new and tumor-specific treatment methods.

In this study, the research of the clinical and pathologic characteristics of the MpBC that determine its rank among all breast cancers was aimed.

Methods

Metaplastic carcinoma of the breast was found in 7 out of 1,164 patients that had a diagnosis of breast cancer within the period of 12 years in our hospital. Demographic and clinical characteristics of the patients were retrieved from the patient files, and their final status was verified by a phone call. Histopathological findings of the patients were evaluated by examining the preparations fixed in formalin and stained with hematoxylen and eosin (H&E). They were immunohistochemically re-evaluated for ER (1/100, clone EP-1), PR (1/400, SP2), C-erbB-2 (1/800, e2-4001+3B5), CK5/6 (1/100, D5/16B4), and EGFR (1/25, EP38Y). Hormone receptors, nuclear staining, and the reaction intensity of the tumor cells were evaluated immunohistochemically. The staining percentage of the tumor cell nuclei was noted. Estrogen receptors and PR were considered positive if the nuclear staining was more than 10%. Regarding C-erbB-2 staining, the lack of staining on tumor cells or incomplete membrane staining <10% was considered as 0. Score 1 – weak and incomplete membrane staining >10%. Score 2 – weak to moderate complete membrane staining >10%. Score 3 – strong complete membrane staining >10%.\textsuperscript{6} Subgroups were determined according to the WHO classification (Table 1).\textsuperscript{4}

Results

All patients were female with a median age of 61 years (41–87 years). Two of them were premenopausal and 1 patient had 2 cases of breast cancer at her pedigree. Clinical and histological findings of the patients with metaplastic cancer are summarized in Table 2.

Two patients had draining wounds due to the tumor. Five patients had tumors with diameters <5 cm. The tumors were multi-centric in 2 patients and were associated with foci of carcinoma in situ. All patients had palpable and multiple axillary lymph nodes. Lymph nodes formed a conglomerate in 1 patient. This patient also had lung, bone and brain metastases at diagnosis.

Two patients were diagnosed with stage IIIB and 1 patient had 3 cycles of neoadjuvant chemotherapy. Modified radical mastectomy was performed in the cases with stages IIA, IIB, and those that had neoadjuvant chemotherapy. Toilet mastectomy was performed in the case of stage IIIB with a draining wound. The patient with stage IV was diagnosed by a core biopsy, but was not operated.

The patient with metastatic disease refused chemotherapy. The 87-year-old patient with stage IV could not have any treatment due to her other health problems.
Two patients did not keep their follow-up and no information could be obtained about their final status. Four patients had CA (doxorubicin and cyclophosphamide) chemotherapy regimen. Two of these patients had paclitaxel treatment for 12 weeks. The patient that was ER and PR positive had 4 cycles of CA and tamoxifen (2 × 10 mg) treatment later. A locally advanced patient had 3 cycles of neoadjuvant and 3 cycles of postsurgical CAF (cyclophosphamide, doxorubicin and 5-Flourourasil) treatment. The median follow-up duration of the patients was 34 (10–58) months. Three out of 5 followed-up cases were disease-free, while 2 of them died due to metastases (Table 3).

**Histological and immunohistochemical analysis**

After the examination of the H&E preparations, 4 patients were demonstrated to have a squamous type of metaplastic cell differentiations, 1 spindle, 1 adenosquamous, and 1 osseous. Six of 7 patients were found to be estrogen and progesterone receptors and C-erbB-2 expression negative. In 1 patient with squamous (adenosquamous) metaplasia, ER was 10% and PR was 5% positive. Conventional fluorescent in situ hybridization (FISH) method did not show any HER2/neu gene amplification upon (+2) C-erB-2 expression score in the same patient. CK5/6 was positive in 5 patients. CK5/6 could not be evaluated in 1 patient despite consequent stains. It was negative in 1 patient. Epidermal growth factor receptor was positive in all patients (Table 4).

### Discussion

DNA microarray and immunohistochemical methods have been quite popular recently in determining the subgroups of breast cancer biologically and clinically. Considering gene expressions, breast cancer that is ER (+) is classified into 2 subgroups as luminal A and luminal B, and ER (−) is classified into 3 subgroups as HER2 expressing, basal-like and null (similar to normal), although there have not been any certain criteria accepted yet. With this classification, we aim to obtain data that would present patient follow-up and treatment choice, demonstrating the molecular basis of the heterogeneity that is observed in breast cancer.

Triple-negative breast cancer (TNBC) is a heterogeneous tumor group that makes 10–20% of all breast cancers and has an aggressive clinical course. 55–80% of TNBC has a basaloid phenotype. Cytokeratin (CK) 14, CK5/6, CK 17, epithelial growth factor receptor (EGFR), p63, CD10, laminin, KIT, nestin, caveolin 1, and NGFR can be used as basal or myoepithelial cell determinant. Basal-like breast cancers show expressions of basal cytokeratin with a high molecular weight (CK5/6, CK14 and CK17), p-kadherin and fascin. In determining basal-like breast cancers, specificity of being ER (−), HER2 (−), CK5/6 and EGFR (+) is 100%, and sensitivity is 76%. In more than 90% of MpBC, CK5/6, CK14 and EGFR expressions are positive, while ER, PR and HER2 are negative immunohistochemically. Estrogen receptor or PR expression frequency is 0–17% in MpBC. All our cases are triple-negative, except the patient in the grey zone. Considering this, all the presented patients can be

### Table 3. Follow-up (7 patients)

<table>
<thead>
<tr>
<th>Follow-up period</th>
<th>58 months</th>
<th>56 months</th>
<th>34 months</th>
<th>10 months</th>
<th>11 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease-free survival</td>
<td>–</td>
<td>–</td>
<td>58 months</td>
<td>56 months</td>
<td>34 months</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>4 cycles of CA</td>
<td>4 cycles of CA</td>
<td>4 cycles of CA</td>
<td>3 + 3 cycles CAF(*)</td>
<td>4 cycles of CA + Paclitaxel</td>
</tr>
<tr>
<td>Survival</td>
<td>alive, disease-free</td>
<td>alive, disease-free</td>
<td>alive, disease-free</td>
<td>alive, disease-free</td>
<td>10 months metastatic</td>
</tr>
<tr>
<td>Differentiation</td>
<td>osseous</td>
<td>squamous</td>
<td>squamous (#)</td>
<td>squamous</td>
<td>spindle</td>
</tr>
</tbody>
</table>

* 3 cycles of neoadjuvant, 3 cycles of adjuvant chemotherapy, # adenosquamous type.

### Table 4. Results of differentiation and immunohistochemical analyses

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>osseous</td>
<td>squamous</td>
<td>squamous (*)</td>
<td>squamous</td>
<td>spindle</td>
<td>squamous</td>
<td>squamous</td>
</tr>
<tr>
<td>ER</td>
<td>–</td>
<td>–</td>
<td>+/+ +/++</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>PR</td>
<td>–</td>
<td>–</td>
<td>+/+ +/++</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CerbB-2</td>
<td>–</td>
<td>–</td>
<td>+/+ +/++</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CK5/6</td>
<td>–</td>
<td>+</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>EGFR</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

* adenosquamous type.
accepted as TNBC. CK5/6 expression could not be evaluated in the case with adenosquamous differentiation, while it was negative in the case with osseous differentiation. MpBC can be evaluated as a subgroup of TNBC considering its immunohistochemical characteristics. Five of the patients presented with squamous differentiation resembled the subgroup of TNBC with a basaoid phenotype. Positivity of the EGFR expression in all cases of MpBC suggests that antiangiogenic treatment alternatives may be helpful.2

Immunohistochemically, C-erbB-2 scoring is a subjective evaluation. C-erbB-2 score was +2 in 1 patient of the group presented. However, there was no HER2/neu gene amplification with the FISH method. ER and PR positivity were within the grey zone limits in this patient. The patient, whose cancer was classified as T1N1M0 (stage IIA), had 4 cycles of AC chemotherapy. The patient used tamoxifen (2 × 10 mg) for 4 years and is disease-free at present.

The incidence of MpBC within breast cancers is reported as 0.02–0.5%.1,2,12 It made 0.6% of the cases that had been diagnosed with breast cancer at our pathology unit during 12 years. Metaplastic cell differentiation with squamous cells was the most frequent. However, 1 patient had sarcomatous changes that showed osseous differentiation.

Metaplastic carcinoma of the breast is mostly seen in the 5th decade. Compared to classical breast carcinoma, tumor size is bigger, axillary lymph node involvement is less frequent and axillary lymph node involvement at the diagnosis is 8–40% in MpBC.5,13–15 Six of the 7 patients presented had a metastatic lymph node. Metaplastic carcinoma of the breast is observed to metastasize to the bones and lungs with hematogeneous spread rather than lymphatic spread. The majority of MpBC tumors is estrogen receptor (ER), progesterone receptor (PR), and HER2 negative, triple-negative breast cancer (TNBC), and usually carries a worse prognosis compared to non-metaplastic TNBC.3,5 Metaplastic carcinoma of the breast is usually more aggressive than pure invasive ductal or invasive lobular cancers often presenting with larger staging (T2, T3); however, lymph node involvement is less likely to be noted.3 The prognosis of MpBC was poorer than that of invasive ductal carcinoma and TNBC; the 5-year overall survival rate was 54.5% in MpBC vs 85.1% in invasive ductal carcinoma and 73.3% in TNBC (p < 0.001).16 In a multicentric study of 405 patients, it was differently reported that there was no difference between ductal breast cancers and MpBC; however, spindle cell type shows aggressive biologic behavior and chemotherapy provides a longer survival in an early stage.17

Clinical findings are like in other breast cancers. MpBC can show benign characteristics at sonography; mammography and MRI as well as findings of invasive carcinoma. It has no specific radiologic findings.13,18 Radiologic findings can change according to the component the tumor contains.19 Metaplastic carcinoma of the breast is seen as a spiculated mass with irregular margins that often has intermediate to high signal intensity in T2W images and is low or isointense in T1W images in MRI.13

Metaplastic carcinoma of the breast may be treated with breast-conserving surgery in suitable cases. It is reported that there is no difference in the survival rate between breast-conserving surgery and a radical mastectomy.1,2,19 However, a modified radical mastectomy is the preferred method of treatment if the tumor is big at diagnosis and local recurrence rate is 35–62% in the first 2–5 years compared to the recurrence rate of 17–20% for invasive ductal carcinoma of similar tumor size.6

There is no specific guideline for the treatment of MpBC. It is known that long-term adjuvant chemotherapy is not useful in such cases.5,21 In 42 out of 47 cases of breast cancer, no survival benefit from adjuvant chemotherapy.5 The heterogeneous nature and sarcoma-like characteristics of MpBC are blamed for the failure of standard chemotherapy schemes.21 Today, for the treatment of MpBC, a high-dose anthracycline is suggested as a chemotherapy regimen in the case of epithelial subgroups. There is a need for new studies that would evaluate different choices of treatment as MpBC has a bad prognosis and an aggressive nature.

In conclusion, MpBC is relatively rare and, in our series, its incidence was 0.6%. According to its immunohistochemical characteristics, MpBC can be interpreted as a subgroup of triple-negative breast cancers (TNBC). Most of the presented patients resembled the subgroup of TNBC with a basaoid phenotype.

References


